New cell therapy trial offers hope for Hard-to-Treat myeloma

NCT ID NCT04155749

Ongoing Disease control Sponsor: Kite, A Gilead Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests experimental cell therapies in 40 adults with relapsed and refractory multiple myeloma who have tried at least three prior treatments. The main goal is to check safety and find the right dose. While not a cure, it aims to control the disease and may lead to better options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED AND REFRACTORY MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED AND REFRACTORY MULTIPLE MYELOMA

Contacts and locations

Locations

Advanced Cellular Therapeutics Facility, DCAM 0800A

Chicago, Illinois, 60637, United States
Beth Israel Deaconess Medical Center

Boston, Massachusetts, 02215, United States
Froedtert Hospital/Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.